Logo image of EXENS.PA

EXOSENS SAS (EXENS.PA) Stock Fundamental Analysis

Europe - EPA:EXENS - FR001400Q9V2 - Common Stock

43.75 EUR
+1.05 (+2.46%)
Last: 9/12/2025, 7:00:00 PM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to EXENS. EXENS was compared to 41 industry peers in the Aerospace & Defense industry. While EXENS has a great health rating, its profitability is only average at the moment. EXENS is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

EXENS had positive earnings in the past year.
EXENS had a positive operating cash flow in the past year.
EXENS.PA Yearly Net Income VS EBIT VS OCF VS FCFEXENS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of 3.54%, EXENS is in line with its industry, outperforming 51.22% of the companies in the same industry.
With a Return On Equity value of 7.14%, EXENS perfoms like the industry average, outperforming 43.90% of the companies in the same industry.
With a Return On Invested Capital value of 7.97%, EXENS perfoms like the industry average, outperforming 56.10% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for EXENS is below the industry average of 9.46%.
The last Return On Invested Capital (7.97%) for EXENS is above the 3 year average (7.01%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.54%
ROE 7.14%
ROIC 7.97%
ROA(3y)2.89%
ROA(5y)N/A
ROE(3y)7.53%
ROE(5y)N/A
ROIC(3y)7.01%
ROIC(5y)N/A
EXENS.PA Yearly ROA, ROE, ROICEXENS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

Looking at the Profit Margin, with a value of 7.79%, EXENS belongs to the top of the industry, outperforming 80.49% of the companies in the same industry.
With an excellent Operating Margin value of 18.28%, EXENS belongs to the best of the industry, outperforming 97.56% of the companies in the same industry.
EXENS has a Gross Margin of 73.86%. This is amongst the best in the industry. EXENS outperforms 97.56% of its industry peers.
In the last couple of years the Gross Margin of EXENS has remained more or less at the same level.
Industry RankSector Rank
OM 18.28%
PM (TTM) 7.79%
GM 73.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5YN/A
EXENS.PA Yearly Profit, Operating, Gross MarginsEXENS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), EXENS is creating some value.
Compared to 1 year ago, EXENS has less shares outstanding
The debt/assets ratio for EXENS has been reduced compared to a year ago.
EXENS.PA Yearly Shares OutstandingEXENS.PA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 100M 200M 300M
EXENS.PA Yearly Total Debt VS Total AssetsEXENS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

EXENS has an Altman-Z score of 4.07. This indicates that EXENS is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.07, EXENS belongs to the best of the industry, outperforming 80.49% of the companies in the same industry.
The Debt to FCF ratio of EXENS is 4.69, which is a neutral value as it means it would take EXENS, 4.69 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of EXENS (4.69) is better than 65.85% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that EXENS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.61, EXENS perfoms like the industry average, outperforming 46.34% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.69
Altman-Z 4.07
ROIC/WACC1.06
WACC7.54%
EXENS.PA Yearly LT Debt VS Equity VS FCFEXENS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 100M 200M 300M 400M

2.3 Liquidity

EXENS has a Current Ratio of 2.51. This indicates that EXENS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 2.51, EXENS belongs to the best of the industry, outperforming 92.68% of the companies in the same industry.
EXENS has a Quick Ratio of 1.67. This is a normal value and indicates that EXENS is financially healthy and should not expect problems in meeting its short term obligations.
EXENS has a better Quick ratio (1.67) than 90.24% of its industry peers.
Industry RankSector Rank
Current Ratio 2.51
Quick Ratio 1.67
EXENS.PA Yearly Current Assets VS Current LiabilitesEXENS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 102.95% over the past year.
The Revenue has grown by 35.04% in the past year. This is a very strong growth!
The Revenue has been growing by 33.36% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)102.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%875.18%
Revenue 1Y (TTM)35.04%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%20.13%

3.2 Future

The Earnings Per Share is expected to grow by 29.99% on average over the next years. This is a very strong growth
Based on estimates for the next years, EXENS will show a quite strong growth in Revenue. The Revenue will grow by 13.86% on average per year.
EPS Next Y57.84%
EPS Next 2Y38.71%
EPS Next 3Y29.99%
EPS Next 5YN/A
Revenue Next Year19.31%
Revenue Next 2Y15.8%
Revenue Next 3Y13.86%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
EXENS.PA Yearly Revenue VS EstimatesEXENS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
EXENS.PA Yearly EPS VS EstimatesEXENS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 59.12, the valuation of EXENS can be described as expensive.
EXENS's Price/Earnings ratio is in line with the industry average.
EXENS's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.30.
EXENS is valuated rather expensively with a Price/Forward Earnings ratio of 22.95.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EXENS indicates a somewhat cheap valuation: EXENS is cheaper than 68.29% of the companies listed in the same industry.
EXENS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.73, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 59.12
Fwd PE 22.95
EXENS.PA Price Earnings VS Forward Price EarningsEXENS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

EXENS's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, EXENS is valued a bit cheaper than 60.98% of the companies in the same industry.
Industry RankSector Rank
P/FCF 38.91
EV/EBITDA 20.63
EXENS.PA Per share dataEXENS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

EXENS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as EXENS's earnings are expected to grow with 29.99% in the coming years.
PEG (NY)1.02
PEG (5Y)N/A
EPS Next 2Y38.71%
EPS Next 3Y29.99%

More info and screens

1

5. Dividend

5.1 Amount

With a yearly dividend of 0.27%, EXENS is not a good candidate for dividend investing.
EXENS's Dividend Yield is slightly below the industry average, which is at 1.19.
Compared to an average S&P500 Dividend Yield of 2.45, EXENS's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.27%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
EXENS.PA Yearly Dividends per shareEXENS.PA Yearly Dividends per shareYearly Dividends per share 2025 0.02 0.04 0.06 0.08

5.3 Sustainability

DPN/A
EPS Next 2Y38.71%
EPS Next 3Y29.99%
EXENS.PA Yearly Income VS Free CF VS DividendEXENS.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 0 50M -50M -100M

More info and screens

EXOSENS SAS

EPA:EXENS (9/12/2025, 7:00:00 PM)

43.75

+1.05 (+2.46%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)07-30 2025-07-30
Earnings (Next)10-27 2025-10-27
Inst Owners42.16%
Inst Owner ChangeN/A
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap2.22B
Analysts78.75
Price Target43.35 (-0.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.27%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.42%
PT rev (3m)11.42%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.85%
EPS NY rev (3m)-0.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.41%
Revenue NY rev (3m)0.5%
Valuation
Industry RankSector Rank
PE 59.12
Fwd PE 22.95
P/S 5.64
P/FCF 38.91
P/OCF 21.97
P/B 5.17
P/tB N/A
EV/EBITDA 20.63
EPS(TTM)0.74
EY1.69%
EPS(NY)1.91
Fwd EY4.36%
FCF(TTM)1.12
FCFY2.57%
OCF(TTM)1.99
OCFY4.55%
SpS7.76
BVpS8.46
TBVpS-0.02
PEG (NY)1.02
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.54%
ROE 7.14%
ROCE 9.7%
ROIC 7.97%
ROICexc 9.07%
ROICexgc 26.62%
OM 18.28%
PM (TTM) 7.79%
GM 73.86%
FCFM 14.49%
ROA(3y)2.89%
ROA(5y)N/A
ROE(3y)7.53%
ROE(5y)N/A
ROIC(3y)7.01%
ROIC(5y)N/A
ROICexc(3y)7.64%
ROICexc(5y)N/A
ROICexgc(3y)25.3%
ROICexgc(5y)N/A
ROCE(3y)8.53%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5YN/A
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.69
Debt/EBITDA 2.32
Cap/Depr 105.56%
Cap/Sales 11.17%
Interest Coverage 250
Cash Conversion 88.9%
Profit Quality 186.1%
Current Ratio 2.51
Quick Ratio 1.67
Altman-Z 4.07
F-Score6
WACC7.54%
ROIC/WACC1.06
Cap/Depr(3y)105.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.64%
Cap/Sales(5y)N/A
Profit Quality(3y)171.48%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%875.18%
EPS Next Y57.84%
EPS Next 2Y38.71%
EPS Next 3Y29.99%
EPS Next 5YN/A
Revenue 1Y (TTM)35.04%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year19.31%
Revenue Next 2Y15.8%
Revenue Next 3Y13.86%
Revenue Next 5YN/A
EBIT growth 1Y45.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.48%
EBIT Next 3Y29.96%
EBIT Next 5YN/A
FCF growth 1Y181.68%
FCF growth 3Y33.59%
FCF growth 5YN/A
OCF growth 1Y90.75%
OCF growth 3Y31.16%
OCF growth 5YN/A